Top-hits for H1N1pdm identified by virtual screening using ensemble-based docking

PLoS Currents

Volumn , Issue , 2011, Pages

  Nguyen, Hung ^a   Le, Lyn ^b   Truong, Thanh N ^c,d  

^a INSTITUTE FOR COMPUTATIONAL SCIENCE AND TECHNOLOGY   (Viet Nam)

^b INTERNATIONAL UNIVERSITY   (Viet Nam)

^c UNIVERSITY OF UTAH   (United States)

^d ICST ^*  (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; SHIKIMIC ACID; SIALIDASE; ZANAMIVIR; GUANIDINE;

ALGORITHM; ARTICLE; HYDROGEN BOND; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOLECULAR DOCKING; MOLECULAR DYNAMICS; SCREENING; VIRUS STRAIN; BINDING AFFINITY; BINDING SITE; CLUSTER ANALYSIS; INFLUENZA A (H1N1); INFLUENZA A (H5N1); NONHUMAN; SCREENING TEST; STATIC ELECTRICITY;

EID: 84867471192     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: 10.1371/currents.RRN1030     Document Type: Article

References (22)

1. Neumann, G.; Noda, T.; Kawaoka, Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459, 931-939.
2. Pandemic (H1N1) 2009 briefing note 4. http://www.who.int/csr/disease/swineflu/notes/h1n1_situation_20090724/en/index.html, (accessed July 26, 2009).
3. First defense against swine flu - seasonal vaccine. http://www.reuters.com/article/asiaCrisis/idUSN24480490, (accessed July 26, 2009).
4. Use of antiviral drugs against influenza A(H1N1). http://www.who.int/csr/disease/swineflu/frequently_asked_questions/swineflu_faq_antivirals/en/index.html, (accessed July 26, 2009).
5. Pandemic (H1N1) 2009 briefing note 1. http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en/, (accessed July 26, 2009).
6. Le, L.; Lee, E.; Schulten, K.; Truong, T. N. Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. Version 2. PLoS Currents: Influenza. 2009 Aug 27 [revised 2009 Aug 27]:RRN1015.
7. Cheng, L. S.; Amaro, R. E.; Xu, D.; Li, W. W.; Arzberger, P. W.; McCammon, J. A. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. J. Med. Chem. 2008, 51, 3878-3894.
8. Hess, B.; Kutzner, C.; van der Spoel, D.; Lindahl, R. GROMACS 4: Algorithms for highly efficient, loadbalanced, and scalable molecular simulation. J. Chem. Theory Comput. 2008, 4 (3), 435-447.
9. Daura, X.; Gademann, K.; Jaun, B.; Seebach, D.; van Gunsteren, W. F.; Mark, A. E. Peptide Folding: When Simulation Meets Experiment. Angew. Chem. Int. Ed. 1999, 38 (1-2), 236-240.
10. Sanner, M. F. A component-based software environment for visualizing large macromolecular assemblies. Structure 2005, 13 (3), 447-462.
11. Gasteiger, J.; Marsili, M. Iterative partial equalization of orbital electronegativity: a rapid access to atomic charges. Tetrahedron 1980, 36 (22), 3219-3228.
12. Lew, W.; Chen, X.; Kim, C. U. Discovery and development of GS4104 (oseltamivir): an orally active influenza neuraminidase inhibitor. Curr. Med. Chem. 2000, 7 (6), 663-672.
13. von Itzstein, M.; Wu, W. Y.; Kok, G. B.; Pegg, M. S.; Dyason, J. C.; Jin, B.; Phan, T. V.; Smythe, M. L.; White, H. F.; Oliver, S. W.; Colman, P. M.; Varghese, J. N.; Ryan, D. M.; Woods, J. M.; Bethell, R. C.; Hotham, V. J.; Cameron, J. M.; Penn, C. R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363, 418-423.
14. Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin, T. H.; Hutchinson, T. L.; Elliott, A. J.; Parker, C. D.; Ananth, S. L.; Horn, L. L.; Laver, G. W.; Montgomery, J. A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43 (19), 3482-3486.
15. Bradley, D. Star role for bacteria in controlling flu pandemic? Nat. Rev. Drug Discov. 2005, 4, 945-946.
16. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comp. Chem. 1998, 19 (14), 1639-1662.
17. Humphrey, W.; Dalke, A.; Schulten, K. VMD - Visual Molecular Dynamics. J. Mol. Graphics 1996, 14 (1), 33-38.
18. Lin, J.-H.; Perryman, A. L.; Schames, J. R.; McCammon, J. A. Computational drug design accommodating receptor flexibility: The relaxed complex scheme. J. Am. Chem. Soc. 2002, 124 (20), 5632-5633.
19. Lin, J.-H.; Perryman, A. L.; Schames, J. R.; McCammon, J. A. The relaxed complex method: Accommodating receptor flexibility for drug design with an improved scoring scheme. Biopolymers 2003, 68 (1), 47-62.
20. Amaro, R. E.; Baron, R.; McCammon, J. A. An improved relaxed complex scheme for receptor flexibility in computer-aided drug design. J. Comput.-Aided Mol. Des. 2008, 22 (9), 693-705.
21. Raffa, R. B. Harmonic mean relationship between affinity for wild-type receptors and alanine-scan mutants. J. Theor. Biol. 2002, 218 (2), 207-214.
22. Zhang, Z. Y.; Thieme-Sefler, A. M.; Maclean, D.; McNamara, D. J.; Dobrusin, E. M.; Sawyer, T. K.; Dixon, J. E. Substrate specificity of the protein tyrosine phosphatases. Proc. Natl. Acad. Sci. U.S.A. 1993, 90 (10), 4446-4450.